AstraZeneca To Break Ground In Russia As MNCs Build Stronger Base In The Country
• By PharmAsia News
Scheduled to break ground in April, AstraZeneca PLC's investment of more than $150 million into construction of a drug manufacturing plant in Russia indicates the U.K.-based firm's confidence and long-term commitment to the emerging Russian market
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
